Compare Prudential PLC (PUK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Summit Therapeutics Inc — how do they compare? Prudential PLC trades at $27.1 (market cap $34.05B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Prudential PLC is far larger — about 2.5× Summit Therapeutics Inc's market cap, and Prudential PLC pays a 2.03% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PUK | SMMT | |
|---|---|---|
Market Cap | $34.05B | $13.79B |
Sector | Financials | Health |
52-Week High | $33.61 | $26.38 |
52-Week Low | $24.98 | $12.43 |
Enterprise Value | $33.60B | $13.11B |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $27.42, down 1.19% with bearish technical signals but strong fundamentals including 14.52% net margin and 19.24% ROE. Recent earnings show mixed results with Q2 2026 missing expectations while maintaining revenue growth to $27.4B in 2025. The company demonstrates improved cash flow generation with $1.93B net cash flow in 2025 and continues shareholder returns through dividends.
The stock presents value with a 9.64 P/E ratio amid analyst optimism (50% buy ratings), though China regulatory risks and technical bearishness warrant caution. Long-term growth prospects in Asian markets and capital return initiatives support investment case, but investors should monitor execution of the five-year strategic reshaping plan.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
